Clinical trials: Antidepressant
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Depression
Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment
The goal of this project is to develop and pilot a mobile smartphone delivered intervention that will improve antidepressant medication care by providing medication adherence monitoring and support to the patient, feedback on…
- Trial name
- Medlink RCT (NCT01909973)
- Testing
- MedLink System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Major Depressive Disorder, Nicotine Dependence
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms
The primary purpose of this study is to determine whether, among smokers with elevated depressive symptoms, sequential antidepressant pharmacotherapy with fluoxetine (20 mg) begun 8 weeks prior to and extended throughout standard…
- Conditions
- Major Depressive Disorder, Nicotine Dependence, Depression
- Trial name
- NCT00578669
- Testing
- Fluoxetine, Dextrose
- Where
- United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Depression
Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects
The aim of the study is to provide insight into the impact of the immunosuppressant drug sirolimus, on the antidepressant effects of the prototypal rapid-acting antidepressant medication, ketamine.
- Trial name
- NCT02487485
- Testing
- Ketamine, sirolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal…
- Trial name
- NCT03434041
- Testing
- Esketamine 56 mg, Esketamine 84 mg, Duloxetine (Oral Antidepressant)
- Where
- 30 sites in United States, China
- Volunteers
- 252 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
5-HTP and Creatine for Depression
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression.
- Trial name
- NCT04395183
- Testing
- 5-Hydroxytryptophan 100 MG, Creatine monohydrate
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Utah
Postpartum Depression, Depression
Clinical Trial of Estrogen for Postpartum Depression
This study evaluates the efficacy of estrogen treatment in women with postpartum depression (PPD). PPD causes significant distress to a large number of women; the demand for effective therapies to treat PPD is considerable.
- Trial name
- NCT00059228
- Testing
- 17beta Estradiol
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Mental Health (NIMH)
Fibromyalgia
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
The intent of this study is to identify and treat fibromyalgia subjects with comorbid depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) primarily…
- Trial name
- NCT01432236
- Testing
- Pregabalin
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
The main goal of this research is to use behavioral, brain, and clinical data to determine which type of antidepressant might be optimal before people with depression start treatment.
- Trial name
- NCT05537584
- Testing
- Sertraline, Bupropion
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Mclean Hospital
Major Depressive Disorder
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®.
- Trial name
- NCT01369030
- Testing
- Deplin®
- Where
- 2 sites in United States
- Volunteers
- 554 people, healthy volunteers welcome
- Sponsor
- Pamlab, Inc.
Depression
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
Investigators will conduct a trial to evaluate the use of Ketamine as an alternate treatment for people with Major Depressive Disorder.
- Trial name
- NCT02106325
- Testing
- Ketamine, Diphenhydramine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- NYU Langone Health
Dysthymic Disorder, Dysthymia
Desvenlafaxine vs. Placebo Treatment of Chronic Depression
The investigators are studying a new antidepressant medicine, desvenlafaxine, for the treatment of people with chronic depression.
- Conditions
- Dysthymic Disorder, Dysthymia, Chronic Depressive Disorder
- Trial name
- NCT01537068
- Testing
- Desvenlafaxine
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
Depression
Emotional and Cognitive Control in Late-Onset Depression
This study may help identify how abnormalities in brain systems that control the ability to ignore irrelevant information may contribute to the development of depression in older adults.
- Trial name
- NCT01728194
- Testing
- Escitalopram, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Major Depressive Disorder
Cysteamine Therapy for Major Depressive Disorder
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
- Trial name
- NCT00715559
- Testing
- cysteamine bitartrate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Premenstrual Dysphoric Disorder
Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
This study will evaluate the effectiveness of sertraline in reducing symptoms in women diagnosed with premenstrual dysphoric disorder.
- Trial name
- NCT00536198
- Testing
- Sertraline
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Yale University
Depression
Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment
This study will determine the effectiveness of an antidepressant in preventing or reducing depressive symptoms in people with melanoma who are receiving Interleukin-2 (IL-2) treatment.
- Trial name
- NCT00352885
- Testing
- Escitalopram, IL-2
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Depressive Disorder, Major
A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.
- Trial name
- NCT04476030
- Testing
- SAGE-217, Sertraline, Escitalopram
- Where
- 51 sites in United States
- Volunteers
- 440 people
- Sponsor
- Biogen
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc